8-K: Acadia Pharmaceuticals Reports Strong Q3 2024 Results, Raises Full-Year Guidance

Acadia Pharmaceuticals announced a profitable third quarter in 2024, driven by strong sales of NUPLAZID and DAYBUE, and updated its full-year financial guidance.

Summary

• Acadia Pharmaceuticals reported total revenues of $250.4 million for the third quarter of 2024, an 18% increase year-over-year.
• NUPLAZID net product sales reached $159.2 million, a 10% increase year-over-year, with a 7% volume growth.
• DAYBUE net product sales were $91.2 million, a 36% increase year-over-year.
• The company achieved net income of $32.8 million, or $0.20 per share, compared to a net loss of $65.2 million in the same period last year.
• For the first nine months of 2024, total revenue was $698.2 million, and net income was $82.7 million, or $0.50 per share.
• Acadia updated its full-year 2024 guidance, narrowing NUPLAZID sales to $600-$610 million, DAYBUE sales to $340-$350 million, and total revenue to $940-$960 million.
• Research and development expenses decreased to $66.6 million for the quarter, primarily due to a large payment in the prior year.
• Selling, general, and administrative expenses increased to $133.3 million due to marketing and commercialization efforts.
• The company's cash, cash equivalents, and investment securities totaled $565.3 million as of September 30, 2024.
• Acadia entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million, with a third of the net proceeds going to Neuren Pharmaceuticals.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, increased sales, and a move to profitability. The sale of the PRV and positive guidance further contribute to the positive outlook. However, increased SG&A expenses and narrowed DAYBUE guidance temper the sentiment slightly.

Positives

• Acadia achieved profitability in Q3 2024, with a net income of $32.8 million.
• Both NUPLAZID and DAYBUE showed strong sales growth, with DAYBUE sales increasing by 36% year-over-year.
• The company's cash position is strong at $565.3 million.
• Acadia is on track to reach over $1 billion in annualized sales in 2025.
• The sale of the PRV for $150 million will provide additional capital.
• DAYBUE received marketing authorization in Canada, expanding its market reach.

Negatives

• Selling, general, and administrative expenses increased to $133.3 million for the quarter.
• The full year 2024 DAYBUE sales guidance was narrowed to the low end of the prior range.
• The full year 2024 SG&A expense guidance was increased.

Risks

• The company is dependent on the continued successful commercialization of NUPLAZID and DAYBUE.
• There are risks associated with clinical trials and their outcomes.
• Acadia relies on third-party collaborators, manufacturers, and suppliers.
• The company faces competition from other products and therapies.
• There is a risk that the sale of the PRV may not close or that the proceeds may not be deployed as anticipated.
• The company needs to obtain regulatory approvals for its product candidates.

Future Outlook

Acadia updated its full-year 2024 guidance, narrowing NUPLAZID sales to $600-$610 million, DAYBUE sales to $340-$350 million, and total revenue to $940-$960 million. The company is on track to reach more than $1 billion in annualized sales in 2025.

Management Comments

• Catherine Owen Adams, Chief Executive Officer, stated that the company's success is reflected in the third quarter results, putting them on track to reach more than $1 billion in annualized sales in 2025.
• The CEO also expressed excitement about the possibilities for Acadia's current portfolio and pipeline, and the potential to enhance shareholder value.

Industry Context

Acadia's results reflect the growing demand for treatments in the neuroscience space, particularly for conditions like Parkinson's disease psychosis and Rett syndrome. The approval of DAYBUE in Canada further expands its market reach and reinforces its position in the rare disease market.

Comparison to Industry Standards

• Acadia's 18% year-over-year revenue growth in Q3 2024 is strong compared to the average growth rate of many established pharmaceutical companies, which often see single-digit growth.
• The 36% year-over-year growth in DAYBUE sales is particularly impressive, indicating strong market uptake for this relatively new treatment for Rett syndrome. This is significantly higher than the growth rates of many other rare disease treatments.
• The company's shift to profitability in Q3 2024 is a positive sign, as many biotech companies struggle to achieve profitability in their early years. This is a significant improvement compared to companies like Biohaven, which has struggled to achieve profitability despite having a blockbuster drug.
• Acadia's R&D expenses decreased significantly due to a one-time payment in the prior year, which is not a typical trend for biotech companies that usually increase R&D spending to advance their pipelines. This is different from companies like Vertex Pharmaceuticals, which consistently invests heavily in R&D.
• The company's cash position of $565.3 million is robust, providing a solid foundation for future growth and development. This is comparable to other mid-cap biotech companies with commercial products.

Related Party Transactions

• Acadia is required to pay Neuren Pharmaceuticals Limited one-third of the net proceeds received from the sale of the PRV.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and potential for future growth.
• Patients will benefit from the continued availability of NUPLAZID and DAYBUE, as well as the development of new therapies.
• Employees may benefit from the company's growth and success.
• The sale of the PRV will provide additional capital for the company's operations.

Next Steps

• Acadia will continue to commercialize NUPLAZID and DAYBUE.
• The company will advance its pipeline assets, including programs for Prader-Willi syndrome and Alzheimer's disease psychosis.
• Acadia will work to close the sale of the PRV.
• The company will host a conference call to discuss the third quarter 2024 results.

Key Dates

Keywords

Acadia Pharmaceuticals, NUPLAZID, DAYBUE, Rett syndrome, Parkinson's disease psychosis, Financial Results, Pharmaceuticals, Biotechnology, Revenue, Net Income, Priority Review Voucher